Literature DB >> 29198021

Alpha-synuclein aggregation, Ubiquitin proteasome system impairment, and L-Dopa response in zinc-induced Parkinsonism: resemblance to sporadic Parkinson's disease.

Vinod Kumar1,2, Deepali Singh1,2, Brajesh Kumar Singh1, Shweta Singh1, Namrata Mittra1,2, Rakesh Roshan Jha3, Devendra Kumar Patel3, Chetna Singh4,5.   

Abstract

Alpha-synuclein (α-synuclein) aggregation and impairment of the Ubiquitin proteasome system (UPS) are implicated in Parkinson's disease (PD) pathogenesis. While zinc (Zn) induces dopaminergic neurodegeneration resulting in PD phenotype, its effect on protein aggregation and UPS has not yet been deciphered. The current study investigated the role of α-synuclein aggregation and UPS in Zn-induced Parkinsonism. Additionally, levodopa (L-Dopa) response was assessed in Zn-induced Parkinsonian model to establish its closeness with idiopathic PD. Male Wistar rats were treated with zinc sulfate (Zn; 20 mg/kg; i.p.) twice weekly for 12 weeks along with respective controls. In few subsets, animals were subsequently treated with L-Dopa for 21 consecutive days following Zn exposure. A significant increase in total and free Zn content was observed in the substantia nigra of the brain of exposed groups. Zn treatment caused neurobehavioral anomalies, striatal dopamine decline, and dopaminergic neuronal cell loss accompanied with a marked increase in α-synuclein expression/aggregation and Ubiquitin-conjugated protein levels in the exposed groups. Zn exposure substantially reduced UPS-associated trypsin-like, chymotrypsin-like, and caspase-like activities along with the expression of SUG1 and β-5 subunits of UPS in the nigrostriatal tissues of exposed groups. L-Dopa treatment rescued from Zn-induced neurobehavioral deficits and restored dopamine levels towards normalcy; however, Zn-induced dopaminergic neuronal loss, reduction in tyrosine hydroxylase expression, and increase in oxidative stress were unaffected. The results suggest that Zn caused UPS impairment, resulting in α-synuclein aggregation subsequently leading to dopaminergic neurodegeneration, and that Zn-induced Parkinsonism exhibited positive L-Dopa response similar to sporadic PD.

Entities:  

Keywords:  L-Dopa; Parkinson’s disease; Ubiquitin proteasome system; Zinc; α-Synuclein aggregation

Mesh:

Substances:

Year:  2017        PMID: 29198021     DOI: 10.1007/s11010-017-3239-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  42 in total

1.  Nitrosative and oxidative stress links dysfunctional ubiquitination to Parkinson's disease.

Authors:  Z Gu; T Nakamura; D Yao; Z-Q Shi; S A Lipton
Journal:  Cell Death Differ       Date:  2005-09       Impact factor: 15.828

2.  Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.

Authors:  Francesco Fornai; Oliver M Schlüter; Paola Lenzi; Marco Gesi; Riccardo Ruffoli; Michela Ferrucci; Gloria Lazzeri; Carla L Busceti; Fabrizio Pontarelli; Giuseppe Battaglia; Antonio Pellegrini; Ferdinando Nicoletti; Stefano Ruggieri; Antonio Paparelli; Thomas C Südhof
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-16       Impact factor: 11.205

3.  Ibuprofen Protects from Cypermethrin-Induced Changes in the Striatal Dendritic Length and Spine Density.

Authors:  Pratibha Tripathi; Ashish Singh; Lakshmi Bala; Devendra Kumar Patel; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2017-03-25       Impact factor: 5.590

4.  Effect of zinc and paraquat co-exposure on neurodegeneration: Modulation of oxidative stress and expression of metallothioneins, toxicant responsive and transporter genes in rats.

Authors:  Ashutosh Kumar; Israr Ahmad; Smriti Shukla; Brajesh Kumar Singh; Devendra Kumar Patel; Haushila Prasad Pandey; Chetna Singh
Journal:  Free Radic Res       Date:  2010-08

5.  Minocycline Rescues from Zinc-Induced Nigrostriatal Dopaminergic Neurodegeneration: Biochemical and Molecular Interventions.

Authors:  Vinod Kumar; Brajesh Kumar Singh; Amit Kumar Chauhan; Deepali Singh; Devendra Kumar Patel; Chetna Singh
Journal:  Mol Neurobiol       Date:  2015-03-13       Impact factor: 5.590

Review 6.  The role of protein clearance mechanisms in organismal ageing and age-related diseases.

Authors:  David Vilchez; Isabel Saez; Andrew Dillin
Journal:  Nat Commun       Date:  2014-12-08       Impact factor: 14.919

7.  Zn2+ mediates ischemia-induced impairment of the ubiquitin-proteasome system in the rat hippocampus.

Authors:  Min Chen; Qian Chen; Xue-Wen Cheng; Ting-Jia Lu; Han-Xing Liu; Jie-Min Jia; Chi Zhang; Li Xu; Zhi-Qi Xiong
Journal:  J Neurochem       Date:  2009-09-24       Impact factor: 5.372

Review 8.  An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.

Authors:  Hayate Javed; Mohammad Amjad Kamal; Shreesh Ojha
Journal:  CNS Neurol Disord Drug Targets       Date:  2016       Impact factor: 4.388

9.  The bipyridyl herbicide paraquat induces proteasome dysfunction in human neuroblastoma SH-SY5Y cells.

Authors:  Wonsuk Yang; Evelyn Tiffany-Castiglioni
Journal:  J Toxicol Environ Health A       Date:  2007-11

10.  Altered proteasomal function in sporadic Parkinson's disease.

Authors:  Kevin St P McNaught; Roger Belizaire; Ole Isacson; Peter Jenner; C Warren Olanow
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

View more
  14 in total

1.  The proteasome as a druggable target with multiple therapeutic potentialities: Cutting and non-cutting edges.

Authors:  G R Tundo; D Sbardella; A M Santoro; A Coletta; F Oddone; G Grasso; D Milardi; P M Lacal; S Marini; R Purrello; G Graziani; M Coletta
Journal:  Pharmacol Ther       Date:  2020-05-19       Impact factor: 12.310

2.  The Zinc Ionophore Clioquinol Reduces Parkinson's Disease Patient-Derived Brain Extracts-Induced Neurodegeneration.

Authors:  Margaux Teil; Evelyne Doudnikoff; Marie-Laure Thiolat; Sylvain Bohic; Erwan Bezard; Benjamin Dehay
Journal:  Mol Neurobiol       Date:  2022-08-02       Impact factor: 5.682

3.  p21-activated kinase 4 controls the aggregation of α-synuclein by reducing the monomeric and aggregated forms of α-synuclein: involvement of the E3 ubiquitin ligase NEDD4-1.

Authors:  So-Yoon Won; Jung-Jin Park; Soon-Tae You; Jong-A Hyeun; Hyong-Kyu Kim; Byung Kwan Jin; Catriona McLean; Eun-Young Shin; Eung-Gook Kim
Journal:  Cell Death Dis       Date:  2022-06-30       Impact factor: 9.685

4.  Zinc.

Authors:  Anatoly V Skalny; Michael Aschner; Alexey A Tinkov
Journal:  Adv Food Nutr Res       Date:  2021-05-24

Review 5.  Synaptic Zinc: An Emerging Player in Parkinson's Disease.

Authors:  Joanna Sikora; Abdel-Mouttalib Ouagazzal
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 6.  Cross-talk between redox signalling and protein aggregation.

Authors:  Loes van Dam; Tobias B Dansen
Journal:  Biochem Soc Trans       Date:  2020-04-29       Impact factor: 5.407

Review 7.  Causative Links between Protein Aggregation and Oxidative Stress: A Review.

Authors:  Elise Lévy; Nadine El Banna; Dorothée Baïlle; Amélie Heneman-Masurel; Sandrine Truchet; Human Rezaei; Meng-Er Huang; Vincent Béringue; Davy Martin; Laurence Vernis
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

Review 8.  Targeting α-synuclein for PD Therapeutics: A Pursuit on All Fronts.

Authors:  Margaux Teil; Marie-Laure Arotcarena; Emilie Faggiani; Florent Laferriere; Erwan Bezard; Benjamin Dehay
Journal:  Biomolecules       Date:  2020-03-03

Review 9.  "Metal elements and pesticides as risk factors for Parkinson's disease - A review".

Authors:  Inam Ullah; Longhe Zhao; Yang Hai; Muhammad Fahim; Dhafer Alwayli; Xin Wang; Hongyu Li
Journal:  Toxicol Rep       Date:  2021-03-10

Review 10.  Current understanding of metal ions in the pathogenesis of Alzheimer's disease.

Authors:  Lu Wang; Ya-Ling Yin; Xin-Zi Liu; Peng Shen; Yan-Ge Zheng; Xin-Rui Lan; Cheng-Biao Lu; Jian-Zhi Wang
Journal:  Transl Neurodegener       Date:  2020-04-03       Impact factor: 8.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.